

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III NATALEE trial demonstrated an improvement in invasive disease-free survival for patients receiving endocrine therapy combined with what dose of ribociclib for HR-positive, HER2-negative localized breast cancer?**
 - a. 150mg
 - b. 400mg**
 - c. 500mg
 - d. 600mg
- 2. Which of the following best describes clinical observations with trastuzumab deruxtecan (T-DXd) for previously treated patients with HER2-null (IHC 0) metastatic breast cancer?**
 - a. No data are available
 - b. Data suggest T-DXd may be efficacious for this population**
 - c. Data suggest T-DXd is not efficacious for this population
- 3. Capiqvartib is directed against which of the following proteins?**
 - a. AKT**
 - b. CDK2
 - c. HER3
 - d. TROP2
- 4. Elacestrant is FDA approved for patients with advanced ER-positive/HER2-negative breast cancer and which of the following characteristics?**
 - a. Newly diagnosed ESR1-wild type disease
 - b. Newly diagnosed ESR1-mutated disease
 - c. ESR1-wild type disease with progression after at least 1 line of endocrine therapy
 - d. ESR1-mutated disease with progression after at least 1 line of endocrine therapy**
 - e. All of the above
- 5. Which of the following statements best describes Phase III clinical trial observations with sacituzumab govitecan in patients with advanced breast cancer?**
 - a. Benefit is observed regardless of TROP2 expression**
 - b. Benefit is limited to patients with high TROP2 expression